var data={"title":"Management of refractory nonmalignant pleural effusions","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Management of refractory nonmalignant pleural effusions</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/contributors\" class=\"contributor contributor_credentials\">David J Feller-Kopman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/contributors\" class=\"contributor contributor_credentials\">V Courtney Broaddus, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 01, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary treatment of a nonmalignant pleural effusion (NMPE) should target the underlying cause of the effusion. Sometimes, nonmalignant effusions persist or recur despite appropriate treatment of the primary process. In this situation, symptomatic pleural effusions are usually treated with intermittent thoracentesis or pleurodesis; other options include placement of an indwelling pleural catheter for intermittent drainage, pleurectomy, or a pleural-peritoneal shunt. NMPE is associated with a high mortality such that prompt management is critical. [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/1,2\" class=\"abstract_t\">1,2</a>] </p><p>In this topic review, strategies for management of refractory nonmalignant pleural effusions are discussed. A diagnostic approach to pleural effusions is provided separately. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">&quot;Diagnostic evaluation of a pleural effusion in adults: Initial testing&quot;</a> and <a href=\"topic.htm?path=diagnostic-evaluation-of-pleural-effusion-in-adults-additional-tests-for-undetermined-etiology\" class=\"medical medical_review\">&quot;Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology&quot;</a>.)</p><p>Options for primary treatment of malignant pleural effusions and specific types of nonmalignant pleural effusion are discussed within those topic reviews. (See <a href=\"topic.htm?path=management-of-malignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of malignant pleural effusions&quot;</a> and <a href=\"topic.htm?path=etiology-clinical-presentation-and-diagnosis-of-chylothorax\" class=\"medical medical_review\">&quot;Etiology, clinical presentation, and diagnosis of chylothorax&quot;</a> and <a href=\"topic.htm?path=parapneumonic-effusion-and-empyema-in-adults\" class=\"medical medical_review\">&quot;Parapneumonic effusion and empyema in adults&quot;</a> and <a href=\"topic.htm?path=pleural-effusions-following-cardiac-surgery\" class=\"medical medical_review\">&quot;Pleural effusions following cardiac surgery&quot;</a> and <a href=\"topic.htm?path=pleural-effusions-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Pleural effusions in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=tuberculous-pleural-effusion\" class=\"medical medical_review\">&quot;Tuberculous pleural effusion&quot;</a> and <a href=\"topic.htm?path=diagnosis-and-management-of-pleural-causes-of-unexpandable-lung\" class=\"medical medical_review\">&quot;Diagnosis and management of pleural causes of unexpandable lung&quot;</a> and <a href=\"topic.htm?path=hepatic-hydrothorax\" class=\"medical medical_review\">&quot;Hepatic hydrothorax&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">INDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary treatment is directed at the underlying cause of the pleural effusion in all patients with nonmalignant pleural effusions (<a href=\"image.htm?imageKey=PULM%2F73530\" class=\"graphic graphic_table graphicRef73530 \">table 1</a> and <a href=\"image.htm?imageKey=PULM%2F54055\" class=\"graphic graphic_table graphicRef54055 \">table 2</a>). Patients who have symptoms due to a pleural effusion that is refractory to primary treatment are candidates for additional therapies. Dyspnea is the most common symptom that necessitates additional therapy.</p><p>Prior to proceeding with more invasive therapy, the underlying cause of the nonmalignant pleural effusion (NMPE) should be reconfirmed and trapped lung excluded. Trapped lung refers to development of a fibrous pleural peel that encases the visceral pleura and prevents the lung from expanding fully. This may occur after an underlying inflammatory condition of the pleura has been successfully treated. (See <a href=\"topic.htm?path=diagnosis-and-management-of-pleural-causes-of-unexpandable-lung#H7\" class=\"medical medical_review\">&quot;Diagnosis and management of pleural causes of unexpandable lung&quot;, section on 'Diagnosis'</a>.)</p><p>Asymptomatic patients do NOT require additional therapeutic intervention</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">TREATMENT OPTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptomatic nonmalignant pleural effusions (NMPEs) that are refractory to primary treatment are typically managed with repeated therapeutic thoracentesis or, for those with frequent recurrences, pleurodesis. Options other than pleurodesis for recurrent effusions include placement of an indwelling pleural catheter for intermittent drainage, pleurectomy, or a pleural-peritoneal shunt. Unfortunately, there are little scientific data to guide the clinician when choosing among these options.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Repeat thoracentesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Repeat therapeutic thoracentesis is a simple approach to managing a NMPE and is appropriate when the effusion reaccumulates slowly enough that repeat procedures do not become burdensome to the patient. In general, if thoracentesis for symptomatic relief is required more often than once a month, more definitive treatments should be considered. (See <a href=\"#H6\" class=\"local\">'Pleurodesis'</a> below and <a href=\"#H11\" class=\"local\">'Other options'</a> below.)</p><p>The technique is largely similar to that used for diagnostic thoracentesis. Briefly, after the effusion is visualized with ultrasound guidance, under sterile technique, topical analgesia is administered and then a catheter is percutaneously advanced between the ribs and into the pleural space. A large volume of pleural fluid (eg, 1 to 1.5 L) is then drained. The procedure can be performed at the bedside or in an office setting with appropriate monitoring. (See <a href=\"topic.htm?path=ultrasound-guided-thoracentesis#H4\" class=\"medical medical_review\">&quot;Ultrasound-guided thoracentesis&quot;, section on 'Technique'</a>.)</p><p>Reexpansion pulmonary edema is a potential complication of therapeutic thoracentesis; however, it is uncommon and generally can be avoided by terminating the procedure if the patient develops chest pain or the pleural pressure drops below -20 cm H<sub>2</sub>O [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/3\" class=\"abstract_t\">3</a>]. A safe threshold rate of pleural fluid removal that avoids reexpansion pulmonary edema has not been identified [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Patients may occasionally develop a drainage-related pneumothorax if the underlying lung cannot reexpand, as with entrapped lung or endobronchial obstruction [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/4\" class=\"abstract_t\">4</a>]. Other complications of therapeutic thoracentesis are the same as those for diagnostic thoracentesis. (See <a href=\"topic.htm?path=ultrasound-guided-thoracentesis#H10\" class=\"medical medical_review\">&quot;Ultrasound-guided thoracentesis&quot;, section on 'Complications'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Contraindications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Therapeutic thoracentesis is not beneficial to patients with pleural effusion due to trapped lung unless another cause for pleural fluid accumulation coexists. In this setting, dyspnea usually will not be relieved and the pleural effusion will rapidly reaccumulate [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/5\" class=\"abstract_t\">5</a>] (see <a href=\"topic.htm?path=diagnosis-and-management-of-pleural-causes-of-unexpandable-lung\" class=\"medical medical_review\">&quot;Diagnosis and management of pleural causes of unexpandable lung&quot;</a>). Additionally, multiple (more than two to three) thoracenteses are typically not recommended as they rarely provide a specific diagnosis and guidelines recommend obtaining a visualized pleural biopsy via medical or surgical thoracoscopy [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Pleurodesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pleurodesis is a procedure that obliterates the pleural space to prevent a recurrent pleural effusion. After draining the effusion, a chemical irritant that induces inflammation and fibrosis is instilled into the pleural space (ie, chemical pleurodesis).</p><p>Chemical pleurodesis, including indications, predictors of success, choice of chemical irritant, procedure, and complications, is discussed in detail separately. Among pleural sclerosants, talc has been most studied; however, head-to-head comparisons with other agents have not been performed in NMPEs. (See <a href=\"topic.htm?path=chemical-pleurodesis\" class=\"medical medical_review\">&quot;Chemical pleurodesis&quot;</a> and <a href=\"topic.htm?path=talc-pleurodesis\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;</a>.)</p><p>We suggest that chemical pleurodesis be used for most symptomatic patients with NMPE whose pleural fluid reaccumulates over the course of days rather than weeks. For these patients, repeat therapeutic thoracentesis is likely to be inadequate. It should be emphasized, however, that &quot;tissue is the issue&quot; and it is crucial to obtain adequate pleural biopsies to rule out malignancy. This is especially true for mesothelioma, which can be difficult to diagnose, and has been shown to be present in approximately 12 percent of patients initially thought to have non-specific pleuritis [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/8\" class=\"abstract_t\">8</a>]. Although scientific studies are lacking, the evidence in favor of chemical pleurodesis for NMPE is outlined in the following sections.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several types of NMPEs have been successfully managed by pleurodesis, including those due to chronic ambulatory peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/9-12\" class=\"abstract_t\">9-12</a>], yellow nail syndrome [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/13,14\" class=\"abstract_t\">13,14</a>], chylothorax [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/15-18\" class=\"abstract_t\">15-18</a>], nephrotic syndrome [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/19\" class=\"abstract_t\">19</a>], lupus pleuritis [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/18\" class=\"abstract_t\">18</a>], and heart failure [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/20-22\" class=\"abstract_t\">20-22</a>]. Chemical pleurodesis in patients with hepatic hydrothorax has traditionally been fraught with high recurrence rates, though more recent data have shown pleurodesis success in up to 80 percent [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"#H12\" class=\"local\">'Hepatic hydrothorax'</a> below.)</p><p>Chemical pleurodesis appears to be effective at managing most NMPE, based on data from several case series [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/9-19,24-26\" class=\"abstract_t\">9-19,24-26</a>]. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among 68 patients with NMPE, <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> was successful in 47 (77 percent) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/26\" class=\"abstract_t\">26</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a series of 24 patients with NMPE, chemical pleurodesis was successful in 80 percent [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/24\" class=\"abstract_t\">24</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another series of 16 patients with nonmalignant effusions, <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> was completely successful in 12 (75 percent) and partially successful in another 3 (19 percent) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/25\" class=\"abstract_t\">25</a>]</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Contraindications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pleurodesis is certain to fail in patients whose lungs do not fully reexpand (eg, trapped lung, lung entrapment, or endobronchial obstruction) because successful pleurodesis requires contact of the visceral and parietal pleura. (See <a href=\"topic.htm?path=diagnosis-and-management-of-pleural-causes-of-unexpandable-lung\" class=\"medical medical_review\">&quot;Diagnosis and management of pleural causes of unexpandable lung&quot;</a>.)</p><p>In addition, recurrent or persistent pleural effusion due to infection should prompt reevaluation of the diagnosis and primary therapy, NOT pleurodesis. (See <a href=\"topic.htm?path=parapneumonic-effusion-and-empyema-in-adults\" class=\"medical medical_review\">&quot;Parapneumonic effusion and empyema in adults&quot;</a> and <a href=\"topic.htm?path=pleural-effusions-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Pleural effusions in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=tuberculous-pleural-effusion\" class=\"medical medical_review\">&quot;Tuberculous pleural effusion&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common adverse sequelae of chemical pleurodesis are transient hypoxemia, fever, pain, and gastrointestinal symptoms [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/27,28\" class=\"abstract_t\">27,28</a>]. Far less commonly, patients may experience respiratory failure, cardiovascular complications, a systemic inflammatory response, empyema, decreased lung volume, and dissemination of the chemical agent. Although most complications have been reported in patients with a malignant pleural effusion, there is no reason to expect that complications will differ in patients with nonmalignant pleural effusions. (See <a href=\"topic.htm?path=chemical-pleurodesis#H16\" class=\"medical medical_review\">&quot;Chemical pleurodesis&quot;, section on 'Complications'</a> and <a href=\"topic.htm?path=talc-pleurodesis\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Controversy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinicians have been concerned about exposing patients with nonmalignant disease to uncommon but potentially severe adverse sequelae related to chemical pleurodesis, particularly with talc [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/29,30\" class=\"abstract_t\">29,30</a>]. In particular, the immediate risks of respiratory failure after <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> and the theoretic long-term risks of pleural calcification or malignancy have been discussed [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/29-31\" class=\"abstract_t\">29-31</a>]. The risk of respiratory failure appears minimal when safeguards are followed, such as limiting the total dose to less than 5 g, using size-calibrated talc (eg, less than 10 percent of particles less than 5 to 10 microns; not available in the United states), NOT combining talc pleurodesis with pleural abrasion, and NOT performing bilateral talc pleurodesis at one sitting. Medical talc does not contain asbestos and mesothelioma has not been reported. (See <a href=\"topic.htm?path=talc-pleurodesis\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Other options</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Additional management options for patients with nonmalignant pleural effusions include placing an indwelling pleural catheter for intermittent external drainage, pleuroperitoneal or pleurovenous shunts for internal drainage, or surgical pleurectomy [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/32-34\" class=\"abstract_t\">32-34</a>]. Experience with these techniques has been limited in patients with nonmalignant pleural effusions. However, the following observations may be helpful:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indwelling catheters provide a means by which fluid is intermittently drained from the pleural space without repeated thoracentesis. Intermittent external drainage via an implanted pleural drainage catheter remains a treatment option in select patients who are not candidates for pleurodesis, and some authors recommend their early use due to a significant number of these patients achieving &quot;spontaneous pleurodesis&quot; from this procedure [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/33,35-37\" class=\"abstract_t\">33,35-37</a>] &#160; As an example, one study reported spontaneous pleurodesis after an average of 111 days in patients with NMPEs; in the same study, for patients with malignant effusions, spontaneous pleurodesis was achieved after 36 days [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/35\" class=\"abstract_t\">35</a>]. Another preliminary study reported that successful pleurodesis was achieved in 80 percent of patients with refractory effusions from congestive heart failure when a tunnelled catheter was placed following talc poudrage pleurodesis [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/34\" class=\"abstract_t\">34</a>]. In contrast, the success rate was only 20 percent in patients who only had a tunnelled catheter placed without pleurodesis. A meta-analysis found an overall pleurodesis success rate of 51 percent, with an infectious complication rate of 5 percent [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/38\" class=\"abstract_t\">38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As with patients with malignant effusions, the combination of <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> and IPCs has shown promising results [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/34\" class=\"abstract_t\">34</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pleuroperitoneal shunting successfully palliated 12 patients with nonmalignant pleural effusions [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/39\" class=\"abstract_t\">39</a>]. Pleural empyema was a potential side effect [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/39\" class=\"abstract_t\">39</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pleurovenous shunting (eg, Denver shunt) resulted in successful palliation in 12 patients with right-sided NMPE for the one-year observation period of the study [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/40\" class=\"abstract_t\">40</a>]. Only one patient had a shunt occlusion after four weeks and another had an early but unrelated death.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pleurectomy is generally reserved for patients whose pleural effusion is recurrent despite pleurodesis by less invasive means.</p><p/><p>A more detailed discussion of these techniques is provided separately. (See <a href=\"topic.htm?path=management-of-malignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of malignant pleural effusions&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">HEPATIC HYDROTHORAX</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatic hydrothorax is one of the most difficult forms of nonmalignant pleural effusion (NMPE) to treat. Ideally, these patients should be on maximal medical therapy and if the effusion is still recurrent, transjugular intrahepatic portosystemic shunts (TIPS) and or liver transplantation should be considered [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/41\" class=\"abstract_t\">41</a>]. Unfortunately, many patients are not ideal candidates for either of these procedures, and as such, indwelling pleural catheters (IPCs) and chemical pleurodesis have been proposed [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/23,42,43\" class=\"abstract_t\">23,42,43</a>]. In these patients, ascitic fluid moves rapidly through diaphragmatic defects into the pleural space, due to the pressure difference across the diaphragm [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/44-46\" class=\"abstract_t\">44-46</a>]. As a result, it is often difficult to keep the two pleural surfaces apposed long enough for the inflammatory process to result in pleural symphysis, however a meta-analysis found a success rate of 72 percent, with a similar efficacy and safety profile as TIPS [<a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/47\" class=\"abstract_t\">47</a>]. It should also be noted, that though the risk of infection is low, empyema could potentially remove a patient from the liver transplant waiting list, and as such, definitive pleural interventions such as IPCs or pleurodesis should be made in a multi-disciplinary fashion with the <span class=\"nowrap\">hepatology/transplant</span> teams.</p><p>A management algorithm for hepatic hydrothorax is provided separately. (See <a href=\"topic.htm?path=hepatic-hydrothorax\" class=\"medical medical_review\">&quot;Hepatic hydrothorax&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=pleural-effusion-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Pleural effusion (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary treatment of nonmalignant pleural effusions (NMPEs) is directed at the underlying cause of the pleural effusion in all patients. (See <a href=\"#H2\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who have symptoms due to recurrent or persistent pleural effusion despite therapy directed at the underlying cause are candidates for additional therapies. Asymptomatic patients do not require additional interventions. (See <a href=\"#H2\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior to proceeding with more invasive therapy, the underlying cause of the NMPE should be reconfirmed (with thoracoscopic pleural biopsy) to ensure that primary treatment has been appropriate; infectious causes, hepatic hydrothorax, and trapped lung should also be excluded. (See <a href=\"#H2\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a>, implanted pleural catheters and intermittent drainage, or a combination of the two procedures for patients who have symptoms due to refractory nonmalignant pleural effusions (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H4\" class=\"local\">'Repeat thoracentesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> for patients who have symptoms due to refractory nonmalignant pleural effusions and in whom repeat therapeutic thoracenteses have become burdensome (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). The greatest pleurodesis experience is with talc; however, this choice is controversial due to concerns about immediate and long-term side effects of talc. Pleurodesis, however, should only be performed in this setting after a multi-disciplinary discussion of the risks, benefits, and alternatives. (See <a href=\"#H6\" class=\"local\">'Pleurodesis'</a> above and <a href=\"topic.htm?path=talc-pleurodesis\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the absence of studies examining their efficacy, we do not routinely use pleurectomy, or pleuroperitoneal shunts for nonmalignant pleural effusions. (See <a href=\"#H11\" class=\"local\">'Other options'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H1256705847\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Peter Doelken, MD, FCCP, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/1\" class=\"nounderline abstract_t\">DeBiasi EM, Pisani MA, Murphy TE, et al. Mortality among patients with pleural effusion undergoing thoracentesis. Eur Respir J 2015; 46:495.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/2\" class=\"nounderline abstract_t\">Walker SP, Morley AJ, Stadon L, et al. Nonmalignant Pleural Effusions: A Prospective Study of 356 Consecutive Unselected Patients. Chest 2017; 151:1099.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/3\" class=\"nounderline abstract_t\">Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/4\" class=\"nounderline abstract_t\">Heidecker J, Huggins JT, Sahn SA, Doelken P. Pathophysiology of pneumothorax following ultrasound-guided thoracentesis. Chest 2006; 130:1173.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/5\" class=\"nounderline abstract_t\">Huggins JT, Sahn SA, Heidecker J, et al. Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT. Chest 2007; 131:206.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/6\" class=\"nounderline abstract_t\">Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii4.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/7\" class=\"nounderline abstract_t\">Rahman NM, Ali NJ, Brown G, et al. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii54.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/8\" class=\"nounderline abstract_t\">Davies HE, Nicholson JE, Rahman NM, et al. Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg 2010; 38:472.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/9\" class=\"nounderline abstract_t\">Benz RL, Schleifer CR. Hydrothorax in continuous ambulatory peritoneal dialysis: successful treatment with intrapleural tetracycline and a review of the literature. Am J Kidney Dis 1985; 5:136.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/10\" class=\"nounderline abstract_t\">Simmons LE, Mir AR. A review of management of pleuroperitoneal communication in five CAPD patients. Adv Perit Dial 1989; 5:81.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/11\" class=\"nounderline abstract_t\">Rodriguez-Perez JC, Palop L, Plaza C, et al. Diagnosis and treatment of massive hydrothorax in CAPD. Perit Dial Bull 1984; 4:S49.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/12\" class=\"nounderline abstract_t\">Posen, G, Sachs, H. Treatment of recurrent pleural effusion in dialysis patients by talc insufflation (abstract). Trans Am Soc Artif Intern Organs 1979; 8:75.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/13\" class=\"nounderline abstract_t\">Nordkild P, Kromann-Andersen H, Struve-Christensen E. Yellow nail syndrome--the triad of yellow nails, lymphedema and pleural effusions. A review of the literature and a case report. Acta Med Scand 1986; 219:221.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/14\" class=\"nounderline abstract_t\">Hiller E, Rosenow EC 3rd, Olsen AM. Pulmonary manifestations of the yellow nail syndrome. Chest 1972; 61:452.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/15\" class=\"nounderline abstract_t\">Adler RH, Levinsky L. Persistent chylothorax. Treatment by talc pleurodesis. J Thorac Cardiovasc Surg 1978; 76:859.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/16\" class=\"nounderline abstract_t\">Lieberman J, Agliozzo CM. Intrapleural nitrogen mustard for treating chylous effusion of pulmonary lymphangioleiomyomatosis. Cancer 1974; 33:1505.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/17\" class=\"nounderline abstract_t\">Weissberg D. Talc pleurodesis : a controversial issue. Poumon Coeur 1981; 37:291.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/18\" class=\"nounderline abstract_t\">Vargas FS, Milanez JR, Filomeno LT, et al. Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural effusions. Chest 1994; 106:1771.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/19\" class=\"nounderline abstract_t\">Jenkins PG, Shelp WD. Recurrent pleural transudate in the nephrotic syndrome. A new approach to treatment. JAMA 1974; 230:587.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/20\" class=\"nounderline abstract_t\">Spicer AJ, Fisher JA. Recurring pleural effusion in congestive heart failure treated by pleurodesis. J Ir Med Assoc 1969; 62:177.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/21\" class=\"nounderline abstract_t\">Davidoff D, Naparstek Y, Eliakim M. The use of pleurodesis for intractable pleural effusion due to congestive heart failure. Postgrad Med J 1983; 59:330.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/22\" class=\"nounderline abstract_t\">Audier M, Boutin C, Arnaud A, D'Journo J. [Case of cardiac effusion treated by pleuroscopic talc spray]. Mars Med 1967; 104:866.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/23\" class=\"nounderline abstract_t\">Cerfolio RJ, Bryant AS. Efficacy of video-assisted thoracoscopic surgery with talc pleurodesis for porous diaphragm syndrome in patients with refractory hepatic hydrothorax. Ann Thorac Surg 2006; 82:457.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/24\" class=\"nounderline abstract_t\">Sudduth CD, Sahn SA. Pleurodesis for nonmalignant pleural effusions. Recommendations. Chest 1992; 102:1855.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/25\" class=\"nounderline abstract_t\">Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117:1404.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/26\" class=\"nounderline abstract_t\">Steger V, Mika U, Toomes H, et al. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg 2007; 83:1940.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/27\" class=\"nounderline abstract_t\">Gonzalez AV, Bezwada V, Beamis JF Jr, Villanueva AG. Lung injury following thoracoscopic talc insufflation: experience of a single North American center. Chest 2010; 137:1375.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/28\" class=\"nounderline abstract_t\">Dresler CM, Olak J, Herndon JE 2nd, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/29\" class=\"nounderline abstract_t\">Light RW. Talc should not be used for pleurodesis. Am J Respir Crit Care Med 2000; 162:2024.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/30\" class=\"nounderline abstract_t\">Ghio AJ, Roggli V, Light RW. Talc should not be used for pleurodesis in patients with nonmalignant pleural effusions. Am J Respir Crit Care Med 2001; 164:1741; author reply 1741.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/31\" class=\"nounderline abstract_t\">Sahn SA. Talc should be used for pleurodesis. Am J Respir Crit Care Med 2000; 162:2023.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/32\" class=\"nounderline abstract_t\">Srour N, Potechin R, Amjadi K. Use of indwelling pleural catheters for cardiogenic pleural effusions. Chest 2013; 144:1603.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/33\" class=\"nounderline abstract_t\">Bhatnagar R, Reid ED, Corcoran JP, et al. Indwelling pleural catheters for non-malignant effusions: a multicentre review of practice. Thorax 2014; 69:959.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/34\" class=\"nounderline abstract_t\">Majid A, Kheir F, Fashjian M, et al. Tunneled Pleural Catheter Placement with and without Talc Poudrage for Treatment of Pleural Effusions Due to Congestive Heart Failure. Ann Am Thorac Soc 2016; 13:212.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/35\" class=\"nounderline abstract_t\">Chalhoub M, Harris K, Castellano M, et al. The use of the PleurX catheter in the management of non-malignant pleural effusions. Chron Respir Dis 2011; 8:185.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/36\" class=\"nounderline abstract_t\">Krishnan M, Cheriyath P, Wert Y, Moritz TA. The Untapped Potential of Tunneled Pleural Catheters. Ann Thorac Surg 2015; 100:2055.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/37\" class=\"nounderline abstract_t\">DePew ZS, Iqbal S, Mullon JJ, et al. The role for tunneled indwelling pleural catheters in patients with persistent benign chylothorax. Am J Med Sci 2013; 346:349.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/38\" class=\"nounderline abstract_t\">Patil M, Dhillon SS, Attwood K, et al. Management of Benign Pleural Effusions Using Indwelling Pleural Catheters: A Systematic Review and Meta-analysis. Chest 2017; 151:626.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/39\" class=\"nounderline abstract_t\">Schneider T, Reimer P, Storz K, et al. Recurrent pleural effusion: who benefits from a tunneled pleural catheter? Thorac Cardiovasc Surg 2009; 57:42.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/40\" class=\"nounderline abstract_t\">Artemiou O, Marta GM, Klepetko W, et al. Pleurovenous shunting in the treatment of nonmalignant pleural effusion. Ann Thorac Surg 2003; 76:231.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/41\" class=\"nounderline abstract_t\">Singh A, Bajwa A, Shujaat A. Evidence-based review of the management of hepatic hydrothorax. Respiration 2013; 86:155.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/42\" class=\"nounderline abstract_t\">Northup PG, Harmon RC, Pruett TL, et al. Mechanical pleurodesis aided by peritoneal drainage: procedure for hepatic hydrothorax. Ann Thorac Surg 2009; 87:245.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/43\" class=\"nounderline abstract_t\">Chen A, Massoni J, Jung D, Crippin J. Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax. A Pilot Study. Ann Am Thorac Soc 2016; 13:862.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/44\" class=\"nounderline abstract_t\">Temes RT, Davis MS, Follis FM, et al. Videothoracoscopic treatment of hepatic hydrothorax. Ann Thorac Surg 1997; 64:1468.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/45\" class=\"nounderline abstract_t\">Mouroux J, Perrin C, Venissac N, et al. Management of pleural effusion of cirrhotic origin. Chest 1996; 109:1093.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/46\" class=\"nounderline abstract_t\">Runyon BA, Greenblatt M, Ming RH. Hepatic hydrothorax is a relative contraindication to chest tube insertion. Am J Gastroenterol 1986; 81:566.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-nonmalignant-pleural-effusions/abstract/47\" class=\"nounderline abstract_t\">Hou F, Qi X, Guo X. Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis. Dig Dis Sci 2016; 61:3321.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6694 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">INDICATIONS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">TREATMENT OPTIONS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Repeat thoracentesis</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">- Contraindications</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">Pleurodesis</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">- Efficacy</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Contraindications</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Complications</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Controversy</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">Other options</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">HEPATIC HYDROTHORAX</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H175664174\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1256705847\" id=\"outline-link-H1256705847\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/6694|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/73530\" class=\"graphic graphic_table\">- Transudative pleural effusions</a></li><li><a href=\"image.htm?imageKey=PULM/54055\" class=\"graphic graphic_table\">- Exudative pleural effusions</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=chemical-pleurodesis\" class=\"medical medical_review\">Chemical pleurodesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-management-of-pleural-causes-of-unexpandable-lung\" class=\"medical medical_review\">Diagnosis and management of pleural causes of unexpandable lung</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">Diagnostic evaluation of a pleural effusion in adults: Initial testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-pleural-effusion-in-adults-additional-tests-for-undetermined-etiology\" class=\"medical medical_review\">Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-clinical-presentation-and-diagnosis-of-chylothorax\" class=\"medical medical_review\">Etiology, clinical presentation, and diagnosis of chylothorax</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatic-hydrothorax\" class=\"medical medical_review\">Hepatic hydrothorax</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-malignant-pleural-effusions\" class=\"medical medical_review\">Management of malignant pleural effusions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=parapneumonic-effusion-and-empyema-in-adults\" class=\"medical medical_review\">Parapneumonic effusion and empyema in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pleural-effusion-the-basics\" class=\"medical medical_basics\">Patient education: Pleural effusion (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pleural-effusions-following-cardiac-surgery\" class=\"medical medical_review\">Pleural effusions following cardiac surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pleural-effusions-in-hiv-infected-patients\" class=\"medical medical_review\">Pleural effusions in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=talc-pleurodesis\" class=\"medical medical_review\">Talc pleurodesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculous-pleural-effusion\" class=\"medical medical_review\">Tuberculous pleural effusion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ultrasound-guided-thoracentesis\" class=\"medical medical_review\">Ultrasound-guided thoracentesis</a></li></ul></div></div>","javascript":null}